Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human Subjects
Status:
Completed
Trial end date:
2023-04-25
Target enrollment:
Participant gender:
Summary
An open label, balanced, randomized, two-sequence, two-treatment, two-period, single oral
dose, crossover, bioequivalence study in normal, healthy, adult, human subjects under fasting
condition